U.S. Pain submitted letters on three key federal topic this month: a proposed measure for tracking opioid abuse across health plans; the reauthorization of an act on the drug evaluation process; and whether manufacturers should be allowed to communicate about off-label uses of medications.
NCQA proposed measure changes
Last month, U.S. Pain submitted comments to the National Committee for Quality Assurance (NCQA) on a proposal for tracking opioid abuse through the Healthcare Effectiveness Data and Information Set (HEDIS) 2018. HEDIS is a tool used by more than 90 percent of America’s health plans to measure performance in areas of care and service.